Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis is a promising biopharmaceutical firm with a strong focus on cancer treatments. The company's current portfolio includes successful products like Cometriq and Cabometyx, with more potential treatments in the pipeline. Despite the potential risks, including generic erosion and upcoming patent expirations, the company's cash generation and share repurchase program make it an attractive investment opportunity for those seeking long-term growth. The recent positive trend in OS benefit for the zanza+ICI regimen in all 3L CRC patients further solidifies our positive outlook for the company.

Bears say

Exelixis is facing a potential setback for its product, Cabometyx, as the dual primary endpoint of overall survival (OS) in the non-liver metastases (NLM) subgroup of the STELLAR-303 pivotal trial evaluating Zanzalintinib in combination with atezolizumab did not reach statistically significant results. However, the company's diversified pipeline and upcoming FDA approval decision on December 6th for Zanzalintinib and Tecentriq in 2+ MSI-high CRC could still yield potential growth opportunities. Key risks for the company include potential setbacks in product development, competitive and partnership risks, and macroeconomic and geopolitical uncertainties.

Exelixis (EXEL) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 13 analysts, Exelixis (EXEL) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.